Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice
- PMID: 9933480
- DOI: 10.1359/jbmr.1999.14.2.256
Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice
Abstract
We report on an in vivo model of human myeloma producing bone disease in irradiated severe combined immunodeficiency disease mice using the human myeloma cell line JJN-3 and its subline JJN-3 T1. The cell lines are not Epstein-Barr virus transformed and produce large amounts of hepatocyte growth factor (HGF). Mice had radiological signs of osteolysis and mild hypercalcemia. Xenografted cells were predominantly found in bone marrow and brown adipose tissue, but also in meninges and liver. Take was documented by histopathological examination, immunophenotyping of cultured bone marrow, and radiography. HGF was detected in serum and bone marrow plasma. Disease generally occurred within 45 days of intravenous inoculation and was signaled by paraparesis or signs of intracranial neoplasia. More than 90% of the mice had take of xenografts. The subline JJN-3 T1 gave more reproducible bone marrow take than the native cell line. Bone histomorphometric examination revealed a 99% reduction in osteoblast counts and a 33% reduction in osteoclast counts in areas of tumor growth. Bone formation rates were reduced by 53%. The results suggest that osteoblastopenia and reduced bone formation is of importance for the occurrence of osteolytic lesions in this model.
Similar articles
-
Pathogenesis of myeloma bone disease.Blood Cells Mol Dis. 2004 Mar-Apr;32(2):290-2. doi: 10.1016/j.bcmd.2004.01.001. Blood Cells Mol Dis. 2004. PMID: 15003820 Review.
-
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.Cancer. 2003 Feb 1;97(3 Suppl):802-12. doi: 10.1002/cncr.11134. Cancer. 2003. PMID: 12548579 Review.
-
Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.Oncol Rep. 2002 Nov-Dec;9(6):1237-44. Oncol Rep. 2002. PMID: 12375027
-
An in vivo model of human multiple myeloma bone disease.Stem Cells. 1995 Aug;13 Suppl 2:48-50. Stem Cells. 1995. PMID: 8520511
-
Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.Cancer Res. 1993 Mar 15;53(6):1392-6. Cancer Res. 1993. PMID: 8443818
Cited by
-
The Critical Role of Imaging in the Management of Multiple Myeloma.Curr Hematol Malig Rep. 2017 Jun;12(3):168-175. doi: 10.1007/s11899-017-0379-9. Curr Hematol Malig Rep. 2017. PMID: 28317080 Review.
-
Preclinical animal models of multiple myeloma.Bonekey Rep. 2016 Feb 3;5:772. doi: 10.1038/bonekey.2015.142. eCollection 2016. Bonekey Rep. 2016. PMID: 26909147 Free PMC article.
-
Excess TGF-β mediates muscle weakness associated with bone metastases in mice.Nat Med. 2015 Nov;21(11):1262-1271. doi: 10.1038/nm.3961. Epub 2015 Oct 12. Nat Med. 2015. PMID: 26457758 Free PMC article.
-
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.PLoS One. 2015 Mar 13;10(3):e0119546. doi: 10.1371/journal.pone.0119546. eCollection 2015. PLoS One. 2015. PMID: 25768011 Free PMC article.
-
Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.Stem Cell Res Ther. 2013;4(5):111. doi: 10.1186/scrt322. Stem Cell Res Ther. 2013. PMID: 24025590 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases